1
|
Fang JS, Burt JM. Connexin37 Regulates Cell Cycle in the Vasculature. J Vasc Res 2022; 60:73-86. [PMID: 36067749 DOI: 10.1159/000525619] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2022] [Accepted: 06/08/2022] [Indexed: 11/19/2022] Open
Abstract
Control of vascular cell growth responses is critical for development and maintenance of a healthy vasculature. Connexins - the proteins comprising gap junction channels - are key regulators of cell growth in diseases such as cancer, but their involvement in controlling cell growth in the vasculature is less well appreciated. Connexin37 (Cx37) is one of four connexin isotypes expressed in the vessel wall. Its primary role in blood vessels relies on its unique ability to transduce flow-sensitive signals into changes in cell cycle status of endothelial (and perhaps, mural) cells. Here, we review available evidence for Cx37's role in the regulation of vascular growth, vessel organization, and vascular tone in healthy and diseased vasculature. We propose a novel mechanism whereby Cx37 accomplishes this with a phosphorylation-dependent transition between closed (growth-suppressive) and multiple open (growth-permissive) channel conformations that result from interactions of the C-terminus with cell-cycle regulators to limit or support cell cycle progression. Lastly, we discuss Cx37 and its downstream signaling as a novel potential target in the treatment of cardiovascular disease, and we address outstanding research questions that still challenge the development of such therapies.
Collapse
Affiliation(s)
- Jennifer S Fang
- Department of Cell and Molecular Biology, Tulane University, New Orleans, Louisiana, USA
| | - Janis M Burt
- Department of Physiology, University of Arizona, Tucson, Arizona, USA
| |
Collapse
|
2
|
Ranjbari S, Darroudi M, Hatamluyi B, Arefinia R, Aghaee-Bakhtiari SH, Rezayi M, Khazaei M. Application of MXene in the diagnosis and treatment of breast cancer: A critical overview. Front Bioeng Biotechnol 2022; 10:984336. [PMID: 36091438 PMCID: PMC9449700 DOI: 10.3389/fbioe.2022.984336] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2022] [Accepted: 07/26/2022] [Indexed: 12/07/2022] Open
Abstract
Breast cancer is the second most common cancer worldwide. Prognosis and timely treatment can reduce the illness or improve it. The use of nanomaterials leads to timely diagnosis and effective treatment. MXenes are a 2D material with a unique composition of attributes, containing significant electrical conductance, high optical characteristics, mechanical consistency, and excellent optical properties. Current advances and insights show that MXene is far more promising in biotechnology applications than current nanobiotechnology systems. MXenes have various applications in biotechnology and biomedicine, such as drug delivery/loading, biosensor, cancer treatment, and bioimaging programs due to their high surface area, excellent biocompatibility, and physicochemical properties. Surface modifications MXenes are not only biocompatible but also have multifunctional properties, such as aiming ligands for preferential agglomeration at the tumor sites for photothermal treatment. Studies have shown that these nanostructures, detection, and breast cancer therapy are more acceptable than present nanosystems in in vivo and in vitro. This review article aims to investigate the structure of MXene, its various synthesis methods, its application to cancer diagnosis, cytotoxicity, biodegradability, and cancer treatment by the photothermal process (in-vivo and in-vitro).
Collapse
Affiliation(s)
- Sara Ranjbari
- Chemical Engineering Department, Faculty of Engineering, Ferdowsi University of Mashhad, Mashhad, Iran
| | - Mahdieh Darroudi
- Department of Physiology, Faculty of Medicine, Mashhad University of Medical Science, Mashhad, Iran
- Department of Medical Biotechnology and Nanotechnology, School of Science, Mashhad University of Medical Science, Mashhad, Iran
| | - Behnaz Hatamluyi
- Department of Pharmacology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Reza Arefinia
- Chemical Engineering Department, Faculty of Engineering, Ferdowsi University of Mashhad, Mashhad, Iran
| | - Seyed Hamid Aghaee-Bakhtiari
- Department of Medical Biotechnology and Nanotechnology, School of Science, Mashhad University of Medical Science, Mashhad, Iran
| | - Majid Rezayi
- Department of Medical Biotechnology and Nanotechnology, School of Science, Mashhad University of Medical Science, Mashhad, Iran
- Medical Toxicology Research Center, Mashhad University of Medical Science, Mashhad, Iran
- Metabolic Syndrome Research Center, Mashhad University of Medical Science, Mashhad, Iran
- *Correspondence: Majid Rezayi, ; Majid Khazaei,
| | - Majid Khazaei
- Department of Physiology, Faculty of Medicine, Mashhad University of Medical Science, Mashhad, Iran
- Metabolic Syndrome Research Center, Mashhad University of Medical Science, Mashhad, Iran
- *Correspondence: Majid Rezayi, ; Majid Khazaei,
| |
Collapse
|